Invesco
MLTX icon

Invesco’s MoonLake Immunotherapeutics MLTX Stock Holding History

Invesco’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.6M Buy
+139,574
New +$2.31M ﹤0.01% 2426
2024
Q1 		– Sell
-238,231
Closed -$14.4M – 3909
2023
Q4 		$14.4M Sell
238,231
-12,002
-5% -$619K ﹤0.01% 1594
2023
Q3 		$14.3M Sell
250,233
-11,627
-4% -$642K ﹤0.01% 1531
2023
Q2 		$13.4M Buy
261,860
+85,090
+48% +$2.29M ﹤0.01% 1602
2023
Q1 		$3.78M Buy
+176,770
New +$2.97M ﹤0.01% 2353

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Invesco's MLTX Position: Q1 2026 in Review

Invesco opened a new position in MoonLake Immunotherapeutics (MLTX) in Q1 2026: 139,574 shares worth $2.6M. The stake represents ﹤0.01% of the portfolio and ranks #2426 among its holdings. This is a return to the name: Invesco previously reported a position in MLTX as recently as Q4 2023.

Invesco first reported a position in MLTX in Q1 2023 and has held it in 5 quarters since. The position peaked at $14.4M in Q4 2023. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Invesco held 139,574 shares of MoonLake Immunotherapeutics worth $2.6M as of Q1 2026.
  • MoonLake Immunotherapeutics was a new Invesco position in Q1 2026.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #2426 holding.
  • Invesco first reported a position in MoonLake Immunotherapeutics in Q1 2023 and has held it in 5 quarters since.
  • Invesco's MoonLake Immunotherapeutics position peaked at $14.4M in Q4 2023.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.